生物技术 是本所业务分支,下属于 生命科学.
为生物技术提供领先的知识产权保护
从业50多年来,飞翰曾与多家领先的生物技术公司合作,共同制定和实施成功的知识产权策略,包括为新发明申办专利、在诉讼中执行专利以及就他人提出的侵权指控或产权拥有提供辩护。飞翰曾担任礼来公司(Eli Lilly and Company)的代理人,并在涉及首个由生物技术生产并上市销售的产品—人体胰岛素—的诉讼中取得胜诉。我们提供的咨询或诉讼服务涉及多种技术,例如DNA自动测序、克隆羊多利(Dolly the sheep)、 胎儿染色体异常的无创方法检测、以及抗体平台的设计。
精通法律、科学与技术
对于生物技术行业而言,有力的知识产权保护是发展的根本保障,也是继续成长的关键。作为一家由科学家和生物技术工程师组成的知识产权律所,飞翰在这发展日新月异且多学科综合的行业内始终与迅速发展的科学和不断变化的法律事务保持同步。
随着生物技术企业客户以超乎我们想象的方式取得令人兴奋的突破,我们帮助处理:
我们与处于以下科技发展前沿的客户合作:
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
IPR2022-01200, PGR2022-00051, PTAB, Judges Newman, Snedden, Wisz
22-2232, Fed. Cir.
PGR2022-00037, PTAB, Judges Newman, Obermann, Worth
IPR2022-00738, -00739, -00796, PTAB, Judges Cotta, Wisz, Worth
1:21-cv-10954, D. Mass., Judge Burroughs
T 0527/17, EPO
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Webinar
February 15, 2024
Webinar
Press Release
Finnegan Continues to Hold Top-Tier LMG Life Sciences 2022 Rankings
September 22, 2022
Press Release
ITC Determines Healthgen’s Medium Grade Products Did Not Infringe Ventria’s Patent
September 16, 2022
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.